Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference
Ultragenyx Pharmaceutical (NASDAQ: RARE) will have CEO Emil D. Kakkis present at the Goldman Sachs 42nd Annual Healthcare Conference on June 10, 2021, at 3:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ultragenyx Pharmaceutical (NASDAQ: RARE) will have CEO Emil D. Kakkis present at the Goldman Sachs 42nd Annual Healthcare Conference on June 10, 2021, at 3:00 PM ET. The presentation will be available via a live and archived webcast on the company’s website, accessible for 90 days following the event.
Ultragenyx is focused on developing therapies for serious rare genetic diseases and has a diverse portfolio aimed at addressing high unmet medical needs.
Details
News Market Reaction – RARE
The recorded move for RARE in the trading session of this news was -2.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Goldman Sachs 42nd Annual Healthcare Conference on Thursday, June 10, 2021 at 3:00 PM ET.
The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel therapies for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-475-6370
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.